Jump Financial LLC Has $3.31 Million Holdings in Amicus Therapeutics, Inc. $FOLD

Key Points

• Jump Financial LLC increased its holdings in Amicus Therapeutics by 101.8% in Q1, now owning approximately 406,168 shares valued at $3.31 million.
• Several institutional investors, including PNC Financial Services and GAMMA Investing LLC, have made significant moves in Amicus Therapeutics shares, with PNC boosting its stake by 211.4%.
• Amicus Therapeutics has received varied analyst ratings, with a consensus of a Moderate Buy and an average price target of $16.22, despite recent changes to target prices from firms like Goldman Sachs and UBS Group.

Jump Financial LLC boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 406,168 shares of the biopharmaceutical company's stock after buying an additional 204,941 shares during the period. Jump Financial LLC owned about 0.13% of Amicus Therapeutics worth $3,314,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics during the fourth quarter worth $29,000. PNC Financial Services Group Inc. boosted its stake in Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 3,497 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Amicus Therapeutics during the first quarter worth $53,000. GF Fund Management CO. LTD. acquired a new stake in Amicus Therapeutics during the fourth quarter worth $59,000. Finally, GAMMA Investing LLC raised its stake in Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have issued reports on FOLD shares. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. The Goldman Sachs Group dropped their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Finally, UBS Group boosted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

FOLD opened at $7.48 on Tuesday. The company's 50 day simple moving average is $6.38 and its 200-day simple moving average is $7.15. The stock has a market capitalization of $2.31 billion, a P/E ratio of -62.33 and a beta of 0.53. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.